跳转至内容
Merck
CN
  • Diagnostic tests and treatment options in glomerular disease: 2014 update.

Diagnostic tests and treatment options in glomerular disease: 2014 update.

American journal of kidney diseases : the official journal of the National Kidney Foundation (2013-11-19)
Jonathan Hogan, Prince Mohan, Gerald B Appel
摘要

Glomerular diseases historically have been challenging disorders to comprehend and treat for patients and physicians alike. Kidney biopsy is the gold standard of diagnosis, but the link between pathophysiology and the histologic representation of kidney injury has remained elusive in many of these diseases. As a result, treatment of glomerular disease usually involves therapies that are not specific to disease pathogenesis, such as blockade of the renin-angiotensin-aldosterone system and various immunosuppression regimens. Recent research has resulted in greater insight into some glomerular diseases, leading to the hope that new diagnostic tests and treatments targeting disease-specific mechanisms are on the horizon. We review recent progress on the understanding, diagnosis, and treatment of 4 glomerular diseases: immunoglobulin A nephropathy, focal segmental glomerulosclerosis, the C3 glomerulopathies, and idiopathic membranous nephropathy.

材料
产品编号
品牌
产品描述

USP
霉酚酸酯, United States Pharmacopeia (USP) Reference Standard
Supelco
霉酚酸标准液 CRM 溶液, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®
霉酚酸酯, European Pharmacopoeia (EP) Reference Standard
吗替麦考酚酯, European Pharmacopoeia (EP) Reference Standard